REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2022.
Recent Highlights
“We are very pleased with the results we delivered in 2022 and continue to see positive adoption heading into 2023,” said Reza Zadno, Chief Executive Officer. “We believe there are several positive factors we have seen that will allow us to continue to execute against our strategic growth plan in 2023, including an expanded field based commercial team, increased surgeon and patient interest, and having secured contracts with many of the large IDNs. We believe these catalysts will further the adoption of our technology to become the standard of care for BPH.”
Fourth Quarter 2022 Financial Results
Revenue for the fourth quarter of 2022 was $23.8 million, an increase of 135% compared to the prior year period. U.S. system revenue was $10.4 million, an increase of 109% compared to the prior year period. Growth was influenced largely by strong underlying demand from high-volume BPH hospitals. As of December 31, 2022, the install base of AquaBeam Robotic Systems in the U.S. was 167 systems. U.S. handpiece and consumable revenue for the quarter was $10.4 million, an increase of 202% compared to the prior year period. International revenue was $2.0 million for the quarter, an increase of approximately 44% compared to the prior year period.
Gross margin for the fourth quarter 2022 was 45% compared to 45% in the prior year period. Gross margin in the fourth quarter of 2022 was negatively impacted by approximately $0.7 million of inventory write-offs. The inventory write-offs were related to a lower manufacturing yield on certain components in the disposable handpiece. This issue was identified early in the fourth quarter of 2022 and resolved in the first quarter of 2023.
Operating expenses in the fourth quarter of 2022 were $35.7 million, compared with $21.3 million in the prior year period. The increase was primarily driven by increased selling, general and administrative expenses to expand the sales organization, increased variable compensation expense, and increased research and development expenses.
Total interest and other expense in the fourth quarter of 2022 was $3.1 million. The Company entered into a new five-year $52-million loan agreement in October 2022. As part of the refinancing, the Company recognized loan extinguishment charges of $3.3 million in the fourth quarter of 2022.
Net loss was $28.2 million for the fourth quarter of 2022, compared to a loss of $18.3 million in the prior year period. Adjusted EBITDA was a loss of $21.7 million for the fourth quarter of 2022, compared to a loss of $14.7 million in the prior year period.
Cash and cash equivalents as of December 31, 2022 totaled $221.9 million, while long-term borrowings totaled $52.0 million.
Full Year 2022 Financial Results
Revenue for the full year 2022 was $75.0 million, compared to $34.5 million for the full year 2021. The growth was primarily driven by increases in U.S. revenues, attributable to system placements and increased utilization.
Gross margin for full year 2022 was 49%, compared to 46% for the full year 2021. Gross margin improvement was primarily attributable to the growth in revenues.
Operating expenses were $117.8 million for the full year 2022, compared to $70.0 million for the full year 2021, an increase of 68% driven primarily by headcount increases and public company operating costs.
Net loss was $87.2 million for the full year 2022, compared to $59.9 million for the full year 2021. Adjusted EBITDA was a loss of $68.0 million for full year 2022, compared to a loss of $47.0 million for the full year 2021.
2023 Financial Guidance
Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).”
Webcast and Conference Call Information
PROCEPT BioRobotics will host a conference call to discuss the fourth quarter 2022 financial results after the market close on Tuesday, February 28, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
Investors interested in listening to the conference call may do so by following one of the below links:
Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Use of Non-GAAP Financial Measures (Unaudited)
This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.
The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
Forward Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2022, statements regarding the potential utilities, values, benefits and advantages of Aquablation® therapy performed using PROCEPT BioRobotics’ products, including AquaBeam® Robotic System, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margin, profitability, operating expenses, installed base growth, commercial momentum, overall business or the overall macroeconomic environment, which may impact customer spending or the Company’s costs. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 28, 2023. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit
https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Business Operations
This email address is being protected from spambots. You need JavaScript enabled to view it.
PROCEPT BioRobotics Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share data)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | $ | 23,777 | $ | 10,138 | $ | 75,014 | $ | 34,473 | ||||||||
| Cost of sales | 13,101 | 5,622 | 37,929 | 18,608 | ||||||||||||
| Gross profit | 10,676 | 4,516 | 37,085 | 15,865 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 9,682 | 5,076 | 28,981 | 18,993 | ||||||||||||
| Selling, general and administrative | 26,034 | 16,271 | 88,828 | 51,036 | ||||||||||||
| Total operating expenses | 35,716 | 21,347 | 117,809 | 70,029 | ||||||||||||
| Loss from operations | (25,040 | ) | (16,831 | ) | (80,724 | ) | (54,164 | ) | ||||||||
| Interest expense | (866 | ) | (1,441 | ) | (5,183 | ) | (5,810 | ) | ||||||||
| Interest and other income, net | 992 | (76 | ) | 2,011 | 121 | |||||||||||
| Loss on loan extinguishment | (3,258 | ) | — | (3,258 | ) | — | ||||||||||
| Net loss | $ | (28,172 | ) | (18,348 | ) | (87,154 | ) | (59,853 | ) | |||||||
| Net loss per share, basic and diluted | $ | (0.63 | ) | $ | (0.42 | ) | $ | (1.96 | ) | $ | (3.63 | ) | ||||
| Weighted-average common shares used to | ||||||||||||||||
| Compute net loss per share attributable to | ||||||||||||||||
| Common shareholders, basic and diluted | 44,770 | 43,540 | 44,400 | 16,480 | ||||||||||||
PROCEPT BioRobotics Corporation
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(Unaudited, in thousands)
| Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net loss | $ | (28,172 | ) | $ | (18,348 | ) | $ | (87,154 | ) | $ | (59,853 | ) | ||||
| Depreciation and amortization expense | 663 | 763 | 2,841 | 3,324 | ||||||||||||
| Stock-based compensation expense | 2,885 | 1,496 | 10,337 | 3,796 | ||||||||||||
| Interest (income) and interest expense, net | (320 | ) | 1,414 | 2,687 | 5,735 | |||||||||||
| Loss on loan extinguishment | $ | 3,258 | $ | — | $ | 3,258 | $ | — | ||||||||
| Adjusted EBITDA | $ | (21,686 | ) | $ | (14,675 | ) | $ | (68,031 | ) | $ | (46,998 | ) | ||||
PROCEPT BioRobotics Corporation
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2023 EBITDA Guidance
(Unaudited, in thousands)
| 2023 | ||||
| Net loss | $ | (99,925 | ) | |
| Depreciation and amortization expense | 5,025 | |||
| Stock-based compensation expense | 21,200 | |||
| Interest (income) expense and other (income) expense, net | 3,200 | |||
| Adjusted EBITDA | $ | (70,500 | ) | |
PROCEPT BioRobotics Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
| December 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 221,859 | $ | 304,320 | ||||
| Restricted cash, current | 777 | — | ||||||
| Accounts receivable, net | 15,272 | 4,464 | ||||||
| Inventory | 28,543 | 13,147 | ||||||
| Prepaid expenses and other current assets | 6,175 | 4,242 | ||||||
| Total current assets | 272,626 | 326,173 | ||||||
| Restricted cash, non-current | 3,038 | 777 | ||||||
| Property and equipment, net | 8,656 | 5,045 | ||||||
| Operating lease right-of-use assets, net | 23,481 | 3,279 | ||||||
| Intangible assets, net | 1,477 | 1,750 | ||||||
| Other assets | 51 | — | ||||||
| Total assets | $ | 309,329 | $ | 337,024 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 9,391 | $ | 2,029 | ||||
| Accrued compensation | 13,447 | 6,475 | ||||||
| Deferred revenue | 2,855 | 1,025 | ||||||
| Operating leases, current | 2,129 | 2,105 | ||||||
| Other current liabilities | 7,468 | 4,608 | ||||||
| Total current liabilities | 35,290 | 16,242 | ||||||
| Note payable – non-current portion | 51,213 | 50,004 | ||||||
| Operating lease , non-current | 23,975 | 1,991 | ||||||
| Loan facility derivative liability | 1,779 | 1,496 | ||||||
| Other non-current liabilities | — | 200 | ||||||
| Total liabilities | 112,257 | 69,933 | ||||||
| Stockholders’ equity: | ||||||||
| Additional paid-in capital | 545,753 | 528,666 | ||||||
| Accumulated other comprehensive loss | (6 | ) | (54 | ) | ||||
| Accumulated deficit | (348,675 | ) | (261,521 | ) | ||||
| Total stockholders’ equity | 197,072 | 267,091 | ||||||
| Total liabilities and stockholders’ equity | $ | 309,329 | $ | 337,024 | ||||
PROCEPT BioRobotics Corporation
REVENUE BY TYPE AND GEOGRAPHY
(Unaudited, in thousands)
| Three Months Ended | Twelve Months Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| U.S. | ||||||||||||
| System sales and rentals | $ | 10,446 | $ | 5,007 | $ | 36,527 | $ | 19,375 | ||||
| Handpieces and other consumables | 10,361 | 3,435 | 28,543 | 8,893 | ||||||||
| Service | 957 | 302 | 2,698 | 680 | ||||||||
| Total U.S. revenue | 21,764 | 8,744 | 67,768 | 28,948 | ||||||||
| Outside of U.S. | ||||||||||||
| System sales and rentals | 848 | 768 | 3,201 | 2,493 | ||||||||
| Handpieces and other consumables | 904 | 475 | 3,273 | 2,634 | ||||||||
| Service | 261 | 151 | 772 | 398 | ||||||||
| Total outside of U.S. revenue | 2,013 | 1,394 | 7,246 | 5,525 | ||||||||
| Total revenue | $ | 23,777 | $ | 10,138 | $ | 75,014 | $ | 34,473 | ||||
| Last Trade: | US$97.24 |
| Daily Change: | -2.03 -2.04 |
| Daily Volume: | 262,804 |
| Market Cap: | US$5.050B |
November 26, 2024 October 28, 2024 October 28, 2024 October 07, 2024 August 28, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
